# A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

> **NCT01006252** · PHASE3 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 336 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Tasisulam-sodium
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01006252
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 336 (ACTUAL)
- **Why stopped:** More possibly treatment-related deaths on tasisulam-sodium arm.
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006252, "A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01006252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*